Daklinza
Developed to alleviate chronic hepatitis C infection, indicated to target the virus and support sustained virologic response.
- Category
- Antivirals
- Active ingredient
- Daclatasvir
- Supply
- Pharmacy
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 60mg
Daklinza details
- Condition
- Chronic Hepatitis C
- Therapeutic class
- Direct-acting antiviral
- Pharmacological class
- NS5A inhibitor
- Contraindications
- hypersensitivity to daclatasvir; concurrent use of strong inducers of CYP3A4
- Precautions and warnings
- monitor liver enzymes during treatment
- Minor side effects
- headache; fatigue; nausea
- Moderate side effects
- anaemia; insomnia; diarrhoea
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Pharmacist only, dispensed without a prescription
- Manufacturer
- Bristol-Myers Squibb
- Onset Time
- Continuous therapy
- Duration
- 12–24 weeks
- Storage instructions
- Store in a cool dry place.
- Drug interactions
- amiodarone; carbamazepine; phenytoin
- Age restrictions
- Adults
Serious side effects
bradycardia, requires immediate medical attention; liver failure, requires immediate medical attention
Patient summary
Developed to alleviate chronic hepatitis C infection, indicated to target the virus and support sustained virologic response.
Mechanism of action
Daclatasvir inhibits the NS5A protein, which is essential for both viral RNA replication and virion assembly, thus preventing the virus from multiplying.
Pregnancy and breastfeeding
Pregnancy: Should not be used during pregnancy unless necessary. Breastfeeding: Avoid during treatment.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Daklinza
Daklinza contains the active ingredient daclatasvir, a key component in treatments for chronic hepatitis C. Produced by Bristol-Myers Squibb, the medication arrives in a 60mg tablet format. Usage of this medicine centers on supporting patients managing persistent liver concerns, often alongside other targeted antiviral therapies.
Daklinza availability in Asia
Daklinza is registered across six markets including Thailand, Malaysia and the Philippines, with availability also in Indonesia. For expats and individuals living far from a nearby pharmacy, sourcing generic daclatasvir is often a more affordable alternative, as much of the global supply originates from manufacturing facilities in India. As with any antiviral regimen, this medication is best used under a doctor’s care to monitor efficacy.